Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Externally Controlled Clinical Study to Evaluate the Safety and Efficacy of Autologous Natural Killer Cell (CHANK-101) in Patients With Recurrent Glioblastoma

NCT07831161 is registered in ClinicalTrials.gov with Dong-A University Hospital as lead sponsor.

NCT NCT07831161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07831161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Externally Controlled Clinical Study to Evaluate the Safety and Efficacy of Autologous Natural Killer Cell (CHANK-101) in Patients With Recurrent Glioblastoma
Lead sponsor
Dong-A University Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 29, 2026
Completion date
March 31, 2028
Enrollment
60 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma